Periscope Capital’s Liminatus Pharma Warrants LIMNW Stock Holding History

Periscope Capital’s Portfolio LIMNW Stock Details LIMNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.66K	Hold	30,000	–	–	﹤0.01%	505
2026 Q2	$1.98K	Sell	30,000 -17,500	-37%	-$1.21K	﹤0.01%	473
2026 Q1	$1.9K	Hold	47,500	–	–	﹤0.01%	423
2025 Q4	$1.73K	Hold	47,500	–	–	﹤0.01%	344
2025 Q3	$7.02K	Sell	47,500 -2,500	-5%	-$488	﹤0.01%	275
2025 Q2	$12K	Buy	+50,000	New	+$9.8K	﹤0.01%	210

Other funds holding LIMNW

Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $14.8M AUM 14.32% 1-Year Est. Return

Periscope Capital's LIMNW Position: Q3 2026 in Review

Periscope Capital held its Liminatus Pharma Warrants (LIMNW) position steady in Q3 2026 at 30,000 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #505.

Periscope Capital first reported a position in LIMNW in Q2 2025 and has held it in 6 quarters since. The position peaked at $12K in Q2 2025. 4 funds tracked by Wall St. Rank hold LIMNW as of Q3 2026.

Periscope Capital held 30,000 shares of Liminatus Pharma Warrants worth $1.66K as of Q3 2026.
Periscope Capital left its Liminatus Pharma Warrants share count unchanged in Q3 2026.
Liminatus Pharma Warrants made up ﹤0.01% of Periscope Capital's portfolio in Q3 2026, its #505 holding.
Periscope Capital first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 6 quarters since.
Periscope Capital's Liminatus Pharma Warrants position peaked at $12K in Q2 2025.
4 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q3 2026.

Based on Periscope Capital's 13F filing for Q3 2026, filed 6 Nov 2026.